Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock.

ABSTRACT:

Context

Individuals with type 2 diabetes mellitus (DM) have an increased risk of pneumonia and septic shock. Traditional glucose-lowering drugs have recently been found to be associated with a higher risk of infections. It remains unclear whether sodium-glucose cotransporter 2 inhibitors (SGLT2is), which have pleiotropic/anti-inflammatory effects, may reduce the risk of pneumonia and septic shock in DM.

Methods

MEDLINE, Embase, and ClinicalTrials.gov were searched from inception up to May 19, 2022, for randomized, placebo-controlled trials of SGLT2i that included patients with DM and reported outcomes of interest (pneumonia and/or septic shock). Study selection, data extraction, and quality assessment (using the Cochrane Risk of Bias Assessment Tool) were conducted by indepe

SUBMITTER: Li HL 

PROVIDER: S-EPMC9693836 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature